{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:14:31Z","timestamp":1707524071945},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,12]]},"DOI":"10.7759\/cureus.8584","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T16:57:49Z","timestamp":1591981069000},"source":"Crossref","is-referenced-by-count":0,"title":["Tongue Stiffness as Presentation of Antiphospholipid Syndrome: A Case Report"],"prefix":"10.7759","author":[{"given":"Hana","family":"Rajevac","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Steed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.01840","article-title":"Mechanisms of endothelial dysfunction in antiphospholipid syndrome: association with clinical manifestations","volume":"9","author":"Vel\u00e1squez M","year":"2018","unstructured":"Vel\u00e1squez M, Rojas M, Abrahams VM, Escudero C, \u00c1ngela P. Mechanisms of endothelial dysfunction in antiphospholipid syndrome: association with clinical manifestations. Front Physiol. 2018, 9:1840. 10.3389\/fphys.2018.01840","journal-title":"Front Physiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-020-00759-6","article-title":"[Antiphospholipid syndrome: update on diagnostics and management]","volume":"79","author":"Specker C","year":"2020","unstructured":"Specker C, Fischer-Betz R, D\u00f6rner T. [Antiphospholipid syndrome: update on diagnostics and management]. Z Rheumatol. 2020, 79:255-266. 10.1007\/s00393-020-00759-6","journal-title":"Z Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60709-X","article-title":"Antiphospholipid syndrome","volume":"376","author":"Ruiz-Irastorza G","year":"2010","unstructured":"Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010, 376:1498-1509. 10.1016\/S0140-6736(10)60709-X","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-129627","article-title":"How we diagnose the antiphospholipid syndrome","volume":"113","author":"Giannakopoulos B","year":"2009","unstructured":"Giannakopoulos B, Passam F, Ioannou Y, Krilis SA. How we diagnose the antiphospholipid syndrome. Blood. 2009, 113:985-994. 10.1182\/blood-2007-12-129627","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan D","year":"2013","unstructured":"Erkan D, Vega J, Ram\u00f3n G, Kozora E, Lockshin MD. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 2013, 65:464-471. 10.1002\/art.37759","journal-title":"Arthritis Rheum"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2014.02.005","article-title":"Antiphospholipid antibodies in critically ill patients with cancer: a prospective cohort study","volume":"29","author":"Vassalo J","year":"2014","unstructured":"Vassalo J, Spector N, de Meis E, et al.. Antiphospholipid antibodies in critically ill patients with cancer: a prospective cohort study. J Crit Care. 2014, 29:533-538. 10.1016\/j.jcrc.2014.02.005","journal-title":"J Crit Care"},{"key":"ref7","article-title":"Drug-induced lupus anticoagulants and antiphospholipid antibodies","volume":"14","author":"Dlott JS","year":"2012","unstructured":"Dlott JS, Roubey RAS. Drug-induced lupus anticoagulants and antiphospholipid antibodies. Curr Rheumatol Rep. 2012, 14:71-78. doi: 10.1007\/s11926-011-0227-1","journal-title":"Curr Rheumatol Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316637431","article-title":"The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus","volume":"25","author":"Taraborelli M","year":"2016","unstructured":"Taraborelli M, Leuenberger L, Lazzaroni MG, et al.. The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus. Lupus. 2016, 25:1365. 10.1177\/0961203316637431","journal-title":"Lupus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2016.10.004","article-title":"The antiphospholipid syndrome in patients with systemic lupus erythematosus","volume":"76","author":"Pons-Estel GJ","year":"2017","unstructured":"Pons-Estel GJ, Andreoli L, Scanzi F, Cervera R, Tincani A. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun. 2017, 76:10-20. 10.1016\/j.jaut.2016.10.004","journal-title":"J Autoimmun"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314545410","article-title":"Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: A nationwide prospective study","volume":"23","author":"Mustonen P","year":"2014","unstructured":"Mustonen P, Lehtonen KV, Javela K, et al.. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: A nationwide prospective study. Lupus. 2014, 23:1468-1476. 10.1177\/0961203314545410","journal-title":"Lupus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-340232","article-title":"Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study","volume":"118","author":"Pengo V","year":"2011","unstructured":"Pengo V, Ruffatti A, Legnani C, et al.. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011, 118:4714-4718.  10.1182\/blood-2011-03-340232","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-016-0630-5","article-title":"Short episodes of stiffness of the tongue as an isolated symptom of a foramen magnum meningioma","volume":"117","author":"Depreitere A","year":"2017","unstructured":"Depreitere A, Maes J, Vantomme N. Short episodes of stiffness of the tongue as an isolated symptom of a foramen magnum meningioma. Acta Neurol Belg. 2017, 117:551-553. 10.1007\/s13760-016-0630-5","journal-title":"Acta Neurol Belg"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001140","article-title":"What are white matter hyperintensities made of? Relevance to vascular cognitive impairment","volume":"4","author":"Wardlaw JM","year":"2015","unstructured":"Wardlaw JM, Vald\u00e9s Hern\u00e1ndez MC, Mu\u00f1oz-Maniega S. What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. J Am Heart Assoc. 2015, 4:001140. 10.1161\/JAHA.114.001140","journal-title":"J Am Heart Assoc"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1016\/j.rdc.2006.05.010","article-title":"Cerebral manifestations in the antiphospholipid (Hughes) syndrome","volume":"32","author":"Sanna G","year":"2006","unstructured":"Sanna G, D'Cruz D, Cuadrado MJ. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum Dis Clin North Am. 2006, 32:465-490.","journal-title":"Rheum Dis Clin North Am"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1157\/13074395","article-title":"Neurological manifestations of antiphospholipid syndrome","volume":"124","author":"Su\u00e1rez Alvarez L","year":"2005","unstructured":"Su\u00e1rez Alvarez L, Hughes GR, Khamashta MA. Neurological manifestations of antiphospholipid syndrome. Med Clin (Barc). 2005, 124:630-633. 10.1157\/13074395","journal-title":"Med Clin (Barc)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200001000-00006","article-title":"Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients","volume":"79","author":"Cuadrado MJ","year":"2000","unstructured":"Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T, Simon MJ, Hughes GR. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients. Medicine (Baltimore). 2000, 79:57-68. 10.1097\/00005792-200001000-00006","journal-title":"Medicine (Baltimore)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2014.08.010","article-title":"Neurological antiphospholipid syndrome: clinical, neuroimaging, and pathological characteristics","volume":"346","author":"Zhu DS","year":"2014","unstructured":"Zhu DS, Fu J, Zhang Y, Li SX, Zhang GX, Guan YT, Dong Q. Neurological antiphospholipid syndrome: clinical, neuroimaging, and pathological characteristics. J Neurol Sci. 2014, 346:138-144. 10.1016\/j.jns.2014.08.010","journal-title":"J Neurol Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.20.2278","article-title":"Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings","volume":"166","author":"Tektonidou MG","year":"2006","unstructured":"Tektonidou MG, Varsou N, Kotoulas G, Antoniou A, Moutsopoulos HM. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med. 2006, 166:2278-2784. 10.1001\/archinte.166.20.2278","journal-title":"Arch Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh532","article-title":"Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand?","volume":"44","author":"Ferreira S","year":"2005","unstructured":"Ferreira S, D'Cruz DP, Hughes GRV. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand?  . Rheumatology (Oxford). 2005, 44:434-442. 10.1093\/rheumatology\/keh532","journal-title":"Rheumatology (Oxford)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2005.075861","article-title":"Demyelination in rheumatic diseases","volume":"77","author":"Theodoridou A","year":"2006","unstructured":"Theodoridou A, Settas L. Demyelination in rheumatic diseases. J Neurol Neurosurg Psychiatry. 2006, 77:290-295. 10.1136\/jnnp.2005.075861","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/32422-tongue-stiffness-as-presentation-of-antiphospholipid-syndrome-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:23:18Z","timestamp":1707506598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/32422-tongue-stiffness-as-presentation-of-antiphospholipid-syndrome-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.8584","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,12]]}}}